Medicare Enrolled

Dr. Salman Fazal, M.D.

Hematology & Oncology · Harrisburg, PA
Practice pattern: Clinical Cardiology — Primarily office-based clinical cardiology
Speaking/Promotional
4300 LONDONDERRY RD STE 302, Harrisburg, PA 17109
7177246780
In practice since 2006 (19 years)
NPI: 1588755904 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Fazal from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Fazal? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Fazal

Dr. Salman Fazal is a hematology & oncology specialist in Harrisburg, PA, with 19 years of NPI registration. Based on federal Medicare data, Dr. Fazal performed 705 Medicare services across 273 unique beneficiaries.

Between the years covered by Open Payments, Dr. Fazal received a total of $2,005,428 from 52 pharmaceutical and/or device companies across 1886 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Fazal is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 19 years in practice ▲ Top 41% volume in PA $2,005,428 industry payments

Medicare Practice Summary

Medicare Utilization ↗
705
Medicare services
Top 41% in PA for hematology & oncology
273
Unique beneficiaries
$98
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~37 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

Procedure Volume Avg. paid Avg. submitted
Hospital follow-up visit, high complexity
Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter.
241 $92 $329
Office visit, established patient, complex (40-54 min)
An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter.
218 $122 $528
Office visit, established patient (30-39 min)
A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition.
152 $81 $374
Hospital follow-up visit, moderate complexity
Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service.
50 $60 $217
Initial hospital admission, high complexity
Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter.
20 $126 $536
Hospital discharge management, 30+ min
This service covers the care provided by a physician or qualified healthcare professional on the day a patient is discharged from the hospital. It requires more than 30 minutes of total time spent on the day of discharge.
13 $77 $320
New patient office visit, complex (60-74 min) 11 $169 $647
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.

Industry Payment Transparency

Open Payments through 2024 ↗
$2,005,428
Total received (2018-2024)
Avg $286,490/year across 7 years
Top 0% in PA for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
52
Companies
1,886
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$1,925,298 (96.0%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$78,209 (3.9%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$1,921 (0.1%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$390,136
2023
$361,368
2022
$303,220
2021
$232,413
2020
$190,061
2019
$253,501
2018
$274,728

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
Blueprint Medicines Corporation
$86,549
Janssen Biotech, Inc.
$64,911
Incyte Corporation
$61,514
GlaxoSmithKline, LLC.
$35,056
SOBI, INC
$31,909
Stemline Therapeutics Inc.
$27,065
TAIHO ONCOLOGY, INC.
$20,302
E.R. Squibb & Sons, L.L.C.
$17,791
Kite Pharma, Inc.
$14,739
GENZYME CORPORATION
$8,142
SANOFI-AVENTIS U.S. LLC
$7,460
Karyopharm Therapeutics Inc.
$4,903
Rigel Pharmaceuticals, Inc.
$3,899
Novartis Pharmaceuticals Corporation
$2,362
PharmaEssentia USA Corporation
$1,675
Amgen Inc.
$900
Celgene Corporation
$606
Geron Corporation
$202
ADC Therapeutics America, Inc.
$150
Top 3 companies account for 54.6% of 2024 payments
All-time payments by company (2018-2024) ›
Incyte Corporation
$502,527
Blueprint Medicines Corporation
$193,500
E.R. Squibb & Sons, L.L.C.
$188,005
Janssen Biotech, Inc.
$175,760
Kite Pharma, Inc.
$139,785
Stemline Therapeutics Inc.
$83,592
GlaxoSmithKline, LLC.
$77,076
Celgene Corporation
$62,021
PharmaEssentia USA Corporation
$59,006
Takeda Pharmaceuticals U.S.A., Inc.
$53,554
JAZZ PHARMACEUTICALS INC.
$47,861
Taiho Oncology, Inc.
$47,271
Amgen Inc.
$46,811
Novartis Pharmaceuticals Corporation
$44,423
GENZYME CORPORATION
$42,088
Gilead Sciences, Inc.
$40,638
Janssen Scientific Affairs, LLC
$34,091
SOBI, INC
$31,909
SANOFI-AVENTIS U.S. LLC
$30,468
TAIHO ONCOLOGY, INC.
$20,302
Jazz Pharmaceuticals Inc.
$17,631
Karyopharm Therapeutics Inc.
$16,538
SERVIER PHARMACEUTICALS LLC
$11,082
PFIZER INC.
$7,690
Agios Pharmaceuticals, Inc.
$6,677
Acrotech Biopharma LLC
$6,417
ABBVIE INC.
$5,374
Rigel Pharmaceuticals, Inc.
$3,899
CTI BioPharma Corp.
$3,370
Servier Pharmaceuticals LLC
$1,410
NOVARTIS PHARMACEUTICALS CORPORATION
$1,012
Acceleron Pharma, Inc.
$845
Astellas Pharma US Inc
$600
AbbVie Inc.
$550
BeiGene, Ltd.
$450
Pharmacyclics LLC, An AbbVie Company
$215
Geron Corporation
$202
ADC Therapeutics America, Inc.
$150
United Therapeutics Corporation
$100
Seattle Genetics, Inc.
$100
Genentech USA, Inc.
$98
Alexion Pharmaceuticals, Inc.
$84
Merck Sharp & Dohme Corporation
$50
Pharmacyclics LLC, an AbbVie Company
$49
AbbVie, Inc.
$36
CSL Behring
$19
Shire North American Group Inc
$19
Bayer HealthCare Pharmaceuticals Inc.
$18
Regeneron Healthcare Solutions, Inc.
$16
Teva Pharmaceuticals USA, Inc.
$15
BeiGene USA, Inc.
$14
AstraZeneca Pharmaceuticals LP
$11
Top 3 companies account for 44.1% of all-time payments
Associated products mentioned in payments ›
ABECMA · ABL002 · AYVAKIT · Aliqopa · BELEODAQ · BENDEKA · BESREMI · BLENREP · BOSULIF · BRUKINSA · Blincyto · CALQUENCE · DARZALEX · DEFITELIO · ELITEK · ELZONRIS · EMPLICITI · Fabhalta · GAZYVA · GLEEVEC · ICLUSIG · IDHIFA · IMBRUVICA · INQOVI · INREBIC · Imbruvica · JADENU · JAKAFI · KEYTRUDA · KYMRIAH · Kyprolis · LIBTAYO · MONJUVI · MYLOTARG · NIKTIMVO · NINLARO · NOXAFIL · OJJAARA · ONCASPAR · ONUREG · OPDIVO · Orserdu · PROMACTA · REBLOZYL · REZUROCK · RYDAPT · RYTELO · Reblozyl · Revlimid · Rezlidhia · Rituxan Hycela · SARCLISA · SCEMBLIX · SOLIRIS · SPRYCEL · TASIGNA · TECENTRIQ · TECVAYLI · TIBSOVO · Tecartus · Tibsovo · UNITUXIN · VENCLEXTA · VONJO · VYXEOS · Venclexta · Vonjo · XOSPATA · XPOVIO · Yescarta · ZEJULA · Zydelig
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

The majority of payments (96%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in hematology & oncology and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 0% for hematology & oncology in PA.

Looking for a hematology & oncology specialist in Harrisburg?
Compare hematology & oncology specialists in the Harrisburg area by procedure volume, costs, and industry payment transparency.
Browse hematology & oncology specialists nearby

Geographic Context

Hematology & oncology specialists within 10 mi
57
Per 100K population
19.8
County median income
$74,159
Nearest hospital
UPMC PINNACLE HOSPITALS
3.3 mi

Data Sources

Provider Registry NPPES Weekly updates
Medicare Enrollment PECOS Monthly updates
Practice Data Medicare Util. Annual (CY lag)
Industry Payments Open Payments CY 2024
Disciplinary History — Not public N/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →

Summary

Dr. Fazal is a clinical cardiology specialist, with moderate Medicare volume, with speaking/promotional industry engagement in the top 0% of PA peers, with 19 years of NPI registration.

This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →

Frequently Asked Questions

Is Dr. Fazal experienced with hospital follow-up visit, high complexity?
Based on Medicare claims data, Dr. Fazal performed 241 hospital follow-up visit, high complexity services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Fazal receive payments from pharmaceutical companies?
Yes. Dr. Fazal received a total of $2,005,428 from 52 companies across 1,886 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Fazal's costs compare to other hematology & oncology specialists in Harrisburg?
Dr. Fazal's average Medicare payment per service is $98. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Fazal) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →